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Abstract
Background: Women at risk of preterm delivery receive magnesium sulfate (MgSO4) in the pre-delivery phase to
reduce their child’s risk of neurodevelopmental complications associated with preterm birth. However, the
mechanisms underpinning its placental vascular role remain uncertain.
Methods: The aim of this study was to examine MgSO4 action on vascular tone in male and female human
placental vessels from term and preterm deliveries. Vessels were obtained from placental biopsy following birth
at term (37–41 weeks) or preterm gestation (<36 weeks of gestation). The vessels were mounted on a pressure
myograph, pre-constricted with synthetic endoperoxide prostaglandin PGH2 (U46619) (0.1–100 μmol/l), and percentage
of relaxation was calculated following incubation with bradykinin. Experiments were carried out in the presence of
MgSO4 (0.2 mmol/l), NΨ-nitro-L-arginine methyl ester (L-NAME) (0.1 mmol/l), indomethacin (10 μmol/l), Ca2+-activated
K+ channel blocker TRAM-34 (1 μM) and apamin (3 μM) to assess mechanisms of vascular function. Vascular [calcium
ions (Ca2+)] was analysed using a colorimetric calcium assay.
Results: Vasodilation in vessels from preterm males was significantly blunted in the presence of MgSO4 when
compared to preterm female and term male and female vessels. Overall, MgSO4 was observed to differentially
modulate placental vascular tone and vascular calcium concentrations in a sex-specific manner.
Conclusions: As MgSO4 regulates human placental blood flow via specific pathways, foetal sex-specific MgSO4
treatment regimes may be necessary. In an era of increasing awareness of individualised medicine, sex-specific
effects may be of importance when developing strategies to optimise care in high-risk patients.
Background
Preterm birth is increasingly common, with recent glo-
bal estimates suggesting that as many as 10 % of infants
(approximately 15 million infants per annum) are born
prior to 37 weeks gestation [1, 2]. Although survival
rates for preterm infants have improved, rates of cerebral
palsy (CP), neurodevelopmental delay and cognitive and
behavioural or psychiatric issues are far more prevalent
in infants born preterm when compared to term-born
infants [3, 4]. Although much attention has focused on
infants born at the extremes of gestation, there appears
to be an effect of maturity at birth on later neurological
function that extends the full spectrum of gestational
age [5, 6].
CP is a permanent disorder of motor function due to
disrupted or altered brain development. Its functional
manifestations may evolve with time but there are no
curative therapies currently available. The costs of CP
are significant across a personal as well as global public
health economic platform [7, 8]. In an effort to reduce
CP risk in children born prematurely, obstetric practice
now includes treatment with intravenous magnesium
sulphate (MgSO4) for women at high risk of delivery be-
fore 30 weeks gestation [9]. While the overall efficacy of
this approach has been well described, the number of
women that needed treatment to prevent one case of CP
is relatively high [10]. This suggests that MgSO4 either
has an indirect role in the prevention of CP or that its
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effects are most beneficial to a subgroup of patients.
Male disadvantage in survival and neurological out-
comes in preterm infants has consistently been demon-
strated [11, 12]. However, the neuroprotective effects of
antenatal MgSO4, in terms of sex specificity, have not
yet been reported.
MgSO4 is a modulator of vascular tone [13, 14].
Therefore, the neuroprotective effects of MgSO4 may be
partially mediated via improved placental perfusion, with
improved nutrient transfer to the foetus, especially
within the context of preterm labour. Maturational and
sex-specific differences in vascular flow have already
been identified in preterm infants. Newborn preterm
males demonstrate increased microcirculatory flow com-
pared to either preterm females or term-born infants of
either sex [15]. Therefore, perinatal regulation of vascu-
lar tone may differ according to either gestational age
and/or sex.
MgSO4 has been shown to freely cross the blood-brain
barrier and maternal-placental-foetal interface. In adults,
the physiological concentration of serum magnesium is
1.5 to 2.5 mEq/l (1.8 to 3.0 mg/dl), with approximately
half inactivated, through binding to plasma proteins
[14, 16, 17]. Therapeutic concentrations of maternal
MgSO4 recommended for foetal neuroprotection are
1.8–3.5 mEq/l (2.1 to 4.0 mg/dl). It has been shown
that following maternal MgSO4 treatment, Mg serum
concentrations increase within 60 min and amniotic
fluid concentrations increase after approximately 3 h
[18]. Furthermore, foetal and maternal serum concentra-
tions correlate well with foetal concentrations being ele-
vated 24 h following maternal administration [19]. Despite
well-established treatment regimes, the mechanisms gov-
erning MgSO4 and subsequent placental vascular function
have yet to be defined. In the current study, experimental
concentrations of MgSO4 were determined following a
series of pilot studies in which the in vitro vasodilatory ef-
fects of MgSO4 were tested to the point of saturation
where no further vasodilation was observed. Our study
used a final vessel bath concentration of 3.6 mg/dl of
MgSO4 as this was both within the therapeutic target
range and had been shown to induce changes in vascular
tone in vitro.
There are very few studies characterising the direct
cardiovascular effects of MgSO4. In instrumented animal
models, pregnant ewes treated with MgSO4 during late
gestation have a reduction in maternal mean arterial
pressure, increased uterine artery blood flow and in-
creased foetal oxygenation, without an increase in foetal
heart rate or blood pressure [20, 21]. However, a paucity
of data exists with regard to the effects of MgSO4 on
placental vascular function, and no studies have investi-
gated the effect of MgSO4 on preterm human placental
vasculature function.
Furthermore, the placenta is often generalised as an
asexual organ and any influence of placental sex is rou-
tinely overlooked. However, the human placenta has dis-
tinct sexually dimorphic function. Male and female
placentae have been shown to exhibit differences in glo-
bal gene, protein expression, immune function, steroid
profiles, growth factors, structure and overall function
[22, 23, 24, 25, 26]. Sex-specific differences in vasomotor
function may therefore be apparent in the placental vas-
culature as well as in the new born preterm human. The
current study has used pressure myography to investi-
gate the hypothesis that, in human placental chorionic
plate vessels, there are sexually dimorphic differences in
placental vascular function following MgSO4 treatment.
Methods
Approval for the study was granted by the University of
Otago Human Ethics Committee (H13/058).
Patient eligibility
Eligible women admitted to the Delivery Suite of
Wellington Hospital, Capital and Coast District Health
Board, New Zealand, during the study period were
approached for enrolment in the study. Eligible women
were (i) carrying a singleton foetus with no known con-
genital infection or malformation or genetic or chro-
mosomal abnormalities, (ii) of known gestational age
(confirmed first trimester dating scan), (iii) no maternal
history of pre-eclampsia or foetal growth restriction and
(iv) able to read a patient information sheet and give
written informed consent. The term cohort was com-
prised of women delivering between 37 and 41 weeks of
gestation. The preterm cohort was comprised of women
delivering at less than 36 weeks of gestation who had
not received MgSO4 treatment prior to birth. Gesta-
tional age was ascertained by the mothers’ attending lead
maternity carer or admitting consultant obstetrician. All
patients received obstetric care in accordance with rou-
tine clinical practice, and members of the study team
were not involved in any aspect of the clinical care of
any of the study subjects. The diagnostic criteria for the
patients study eligibility was confirmed by an independ-
ent obstetrician following assessment at the time of ad-
mission and delivery. Term and preterm cohorts were
further divided by infant sex (i.e. male term, female
term, male preterm and female preterm) before statis-
tical analysis. All maternal data were collected from pa-
tient records at the point of delivery.
Sample collection
Following delivery, the placentae were placed on ice
pending biopsy collection. All biopsies were kept on ice
for no longer than 15 min following delivery to dissec-
tion and myography cannulation. A 1-cm3 placental
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biopsy was obtained using a placental measuring gauge
to ensure all biopsies were collected from the same
approximate region of the chorionic foetal side of the
placenta. The biopsies were then placed in an ice-cold
tissue collection buffer (TCB) (119 mM NaCl, 4.7 mM
KCl, 1.6nM CaCl2, 2H20, 24 NaHCO3, 1.18 KH2PO4,
1.2 MgSO4, 0.05 EDTA, 5.5 glucose at pH 7.4) and
remained on ice until studied.
Vascular studies
All chemicals and vasoactive drugs were purchased from
Sigma-Aldrich (Auckland, NZ) unless stated otherwise.
In brief, intact placental chorionic plate vessels (diameter
212 ± 19 μm) were isolated from the placental biopsy
and any remaining connective tissue removed under a
dissecting microscope. The vessel segments were then
mounted on a pressure myograph system (Living
Systems Instrumentation, Burlington, VT, USA). The
foetal vessels were attached to two glass microcannulae
and secured with nylon thread sutures and then further
aligned, so as not to stretch the vessel.
The vessel segments were pressurised to 70 mmHg
following the equilibration period of 30 min or cessation
of vascular activity at 37 °C in TCB gassed with a mix-
ture of 95 % O2 and 5 % CO2. The vessels were allowed
to equilibrate under these conditions for 45 min. There-
after, cumulative concentration response curves were
constructed for the synthetic analogue endoperoxide
prostaglandin H2 (PGH2), U46619 (0.1–100 nmol/l).
Changes in diameter at each U46619 concentration were
compared to the initial vessel diameter as percent
constriction and then normalised as percent max-
imum constriction. Following pre-constriction with
U46619 −log concentration equal to the equivalent pEC80
(concentration equal to 80 % of maximal response) and
cumulative concentration curves were constructed
using the endothelium-dependent vasodilator bradykinin
(10 ρmol/l–1 μmol/l). Following the initial experiments,
bradykinin was used in preference to acetylcholine as it
consistently produced larger and reproducible responses.
Changes in the vessel diameter at each concentration were
compared to the vessel diameter following pre-constriction
with U46619 and then normalised as percentage
relaxation. Following a washout, the concentrations re-
sponse curves were performed in the presence of
various vascular inhibitory drugs. Preliminary experi-
ments determined the dose-dependent effect of MgSO4
(0.05–0.25 mmol/l) on isolated vessels. Concentrations
of MgSO4 were initially determined by previously re-
ported cord blood concentrations following maternal
MgSO4 treatment [27]. A minimum of two vessels per
placenta were analysed and averaged following vascular
experimental protocols. All vasoactive drugs were ap-
plied extraluminally.
To analyse mediators of endothelium-dependent relax-
ation in human placental chorionic plate vessels, the
three main vasodilatory pathways were examined (endo-
thelial-derived hyperpolarising factors (EDHF), nitric
oxide (NO), prostacyclin (PGI2)). To block NO produc-
tion, a non-specific NO synthase inhibitor L-NG-
nitroarginine methyl ester (L-NAME; 0.1 mmol/l) was
used. Indomethacin (INDO; 10 μmol/l) was used to in-
vestigate any vasodilation derived from the cyclo-
oxygenase pathway. The role of EDHF activity in human
chorionic plate vessels is to use the adenosine tri-
phosphate (ATP)-type calcium ions (Ca2+)-activated
K+ channel blocker apamin (3 μM) and intermediate-
conductance Ca2+-activated K+ channel blocker TRAM-34
(1 μM). Inhibitors were used individually and in combin-
ation where stated.
Vascular viability
Alignment and vessel suture integrity was tested by in-
creasing the intraluminal pressure to 70 mmHg, with
further adjustment of the cannulae until the artery was
observed to be aligned. Vessel functional integrity was
assessed by washing the vessel for three 90-s washes
with physiological salt solution (PSS) and pre-
constriction with U46619 (100 nmol/l) (pEC80). Vessels
failing to reproduce consistent constrictions were con-
sidered non-viable and replaced with freshly excised
vessels.
Vascular [Ca2+]
The placental chorionic plate vessels were solubilised
and lysate cleared from solubilised tissue samples by
centrifugation (20,000×g for 10 min). [Ca2+] from the
vessels was determined using a colorimetric Calcium
Detection Kit (Abcam; Cambridge, UK) following the
manufacturer’s instructions.
Statistical analysis
All data are shown as means ± SEM unless stated other-
wise. All observations were made in a minimum of two
vessels per placenta, and the average responses calcu-
lated. n refers to the number of placenta used (two ves-
sels per placenta). Concentration-relaxation curves were
constructed using Prism software (GraphPad Software
Inc., La Jolla, CA, USA.). Pressure myography and vas-
cular calcium concentration data were analysed by using
multifactorial analyses of variance (three-way ANOVA),
with treatment, term and sex as the main factors. Where
significant effects of factor and/or interactions were re-
ported, Bonferroni multiple-comparison post hoc ana-
lysis was performed. P values, F values, and degrees of
freedom are quoted for three-way ANOVA where appro-
priate. A Student t test was employed for the analysis of
basic maternal and neonatal biometrics (Table 1). A
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probability of P < 0.05 was accepted as statistically sig-
nificant. Statistical analysis was performed using SPSS
version 21 (SPSS, Chicago, IL).
Results
Maternal and neonatal biometrics
There was no significant difference observed in mater-
nal age, weight, parity, smoking and alcohol or sub-
stance use between groups (Table 1). Gestational age
was significantly different between term and preterm
births (P < 0.001). Mean gestational age in preterm
males was not significantly different from preterm
females (male, 336 ± 13 weeks vs. female, 335 ± 11 weeks),
and no differences were observed between male and
female term gestational age (male, 392 ± 02 weeks vs.
female, 396 ± 02 weeks).
As expected, term male infants had a greater birth
weight than female infants. Term infants had a greater
birth weight than same-sex preterm infants (term male,
3579 ± 84 g vs. preterm male, 2299 ± 191 g; term female,
3434 ± 79 g vs. preterm female, 1969 ± 283 g, P < 0.01 for
effect of sex and term vs. preterm). Term placentas were
heavier than same-sex preterm placentas (term male,
620 ± 82 g vs. preterm male, 540 ± 72 g, P < 0.05) and
term female, 580 ± 79 g vs. preterm female, 517 ± 91 g,
P < 0.05). There was no effect of sex on placental weight
within either gestational age group (Table 1). All women
enrolled in the study delivered live-born singleton
infants.
Placental chorionic plate vessel responsiveness to
Bradykinin
Bradykinin (10 ρmol/l–1 μmol/l) produced a concentration-
dependent vasodilation in all vessels which was not
different between groups or sex within group. U46619
(0.1–100 μmol/l) produced a concentration-dependent
vasoconstriction in all vessels which was not different
between groups (Fig. 1).
MgSO4 dose-response in placental chorionic plate vessels
Following pre-constriction with U46619 (100 μmol/l), the
vessels were treated with incremental concentrations of
Table 1 Birth and placental weights refer to measurements





(n = 20) (n = 14)
Maternal age (years) 31.1 ± 0.9 29.1 ± 1.5
Maternal weight (kg) 71 ± 2.5 67 ± 2.4
Maternal race or ethnic group (%)
NZ European 73 61
Chinese 12 17
Pacific Islands 15 22
Nulliparous (%) 0 0
Parity 1.7 ± 0.15 1.8 ± 0.1
Twin gestation (%) 0 0
Smoking during pregnancy (%) 0 5 (1 patient)









Male 392 ± 02 336 ± 13
Female 396 ± 02 335 ± 11
Birth weight (g)
Male 3579 ± 83* 2299 ± 191
Female 3434 ± 79* 1969 ± 283
Placental weight (g)
Male 620 ± 82* 540 ± 72
Female 580 ± 79* 517 ± 91
Race or ethnic group was self-reported. n = 20 subjects for term pregnancies
(n = 10 male, n = 10 female) and n = 14 subjects for preterm pregnancies
(n = 7 male, n = 7 female). Data are shown as ± SEM and percentages
where stated
NS not significant
*Denotes statistical significance (P < 0.05) between groups by Student t test
Fig. 1 Relaxation induced by bradykinin following pre-constriction
with U46619 in vessels isolated from male term pregnancies (empty
circle) n = 10, female term pregnancies (empty triangle) n = 10, male
preterm pregnancies (filled circle) n = 7 and female preterm pregnancies
(filled triangle) n = 7. Data was analysed using a repeated measures
three-way ANOVA using treatment × term × sex as the main factors.
All observations were made in a minimum of two vessels per placenta,
and the average responses were calculated before further statistical
analysis. n refers to the number of placenta used. All data are presented
as means ± SEM
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MgSO4 (0.05–0.25 mmol/l). There was no overall effect of
treatment, term or sex. However, a significant interaction
effect (interaction effect = treatment × sex, P = 0.03, F =
11.61, df = 2) was observed. This is likely due to preterm
male vessels having significantly less percentage of relax-
ation than all other groups following MgSO4 administra-
tion. Following post hoc analysis, the placental chorionic
plate vessels from preterm male placentae had a reduced
vasodilatory response (P < 0.01) compared to all other
groups following MgSO4 treatment (0.05, 0.125, 0.15 and
0.20 mmol/l). No further differences were observed at
MgSO4 concentrations of 0.25 mmol/l as all vessels across
all groups appeared to reach the point of saturation with
further doses having no effect on percentage of relaxation
(Fig. 2).
Bradykinin-induced relaxation in placental chorionic plate
vessels incubated with MgSO4
Following pre-constriction with U46619 (100 μmol/l) and
MgSO4 treatment (0.2 mmol/l), bradykinin-induced
vasodilation was observed in a concentration-dependent
manner in all vessels (Fig. 3). There was no overall effect
of treatment, term or sex. However, a significant inter-
action effect (interaction effect = treatment × sex, P = 0.02,
F = 9.376, df = 2) was observed. Following post hoc ana-
lysis, significantly less (P < 0.05) percentage of relaxation
was observed in chorionic plate vessels from preterm male
placental vessels when compared to all other groups.
Bradykinin-induced relaxation in placental chorionic plate
vessels incubated with INDO, L-NAME and MgSO4
Following pre-constriction with U46619 (100 μmol/l) and
administration of MgSO4 (0.2 mmol/l), INDO (10 μmol/l)
and L-NAME (0.1 mmol/l), there was no overall effect of
treatment, term or sex. However, a significant interaction ef-
fect (interaction effect = treatment × sex, P < 0.01, F= 8.213,
df= 2) was observed. Following post hoc analysis, signifi-
cantly less (P < 0.01) percentage of relaxation was signifi-
cantly attenuated in male preterm placental vessels when
compared to female preterm vessels and both male and
female term placental vessels at all −log concentrations of
bradykinin (P < 0.01) (Fig. 4).
Bradykinin-induced relaxation in placental chorionic plate
vessels incubated with TRAM-34, apamin, INDO and
MgSO4
In the presence of MgSO4 (0.4 mmol/l), TRAM-34 (1 μM),
apamin (3 μM) and INDO (10 μmol/l) Bradykinin-induced
vasodilatation did not differ between groups or sex within
group (Fig. 5a).
Bradykinin-induced relaxation in placental chorionic plate
vessels incubated with INDO and MgSO4
In the presence of INDO (10 μmol/l) and MgSO4
(0.2 mmol/l), bradykinin-induced vasodilatation was
Fig. 2 Relaxation induced by incremental concentrations of MgSO4
(0.05–0.25 mmol/l) in vessels isolated from male term pregnancies
(empty circle) n = 10, female term pregnancies (empty triangle) n = 10,
male preterm pregnancies (filled circle) n = 7 and female preterm
pregnancies (filled triangle) n = 7. Data was analysed using a repeated
measures three-way ANOVA using treatment × term × sex as the main
factors. All observations were made in a minimum of two vessels per
placenta, and the average responses were calculated before further
statistical analysis. n refers to the number of placenta used. *Denotes
P < 0.01 in all cases significant difference between male preterm and
all other groups following post hoc analysis. All data are presented
as means ± SEM
Fig. 3 Relaxation induced by bradykinin following pre-constriction
with U46619 and following incubation with MgSO4 (0.2 mmol/l) in
vessels isolated from male term pregnancies (empty circle) n = 10,
female term pregnancies (empty triangle) n = 10, male preterm
pregnancies (filled circle) n = 7 and female preterm pregnancies
(filled triangle) n = 7. Data was analysed using a repeated measures
three-way ANOVA using treatment × term× sex as the main factors.
All observations were made in a minimum of two vessels per placenta,
and the average responses were calculated before further statistical
analysis. n refers to the number of placenta used. *Denotes P< 0.05 in all
cases significant difference between male preterm and all other groups
following post hoc analysis. All data are presented as means ± SEM
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reduced in all groups, but did not differ between groups
or sex within group (Fig. 5b).
Bradykinin-induced relaxation in placental chorionic plate
vessels incubated with TRAM-34 and apamin and MgSO4
In the presence of MgSO4 (0.2 mmol/l), TRAM-34
(1 μM) and apamin (3 μM) bradykinin-induced vasodila-
tation did not differ between group/sex within group
(Fig. 5c).
Vascular calcium concentration
An overall effect of MgSO4 treatment was observed (main
effect of treatment, P < 0.001, F = 9.87, df = 1) on vascular
calcium concentration. MgSO4 significantly reduced vas-
cular calcium concentration in male and female vessels of
both groups (MgSO4 treated vs. MgSO4 untreated; main
effect of term, P < 0.001, F = 5.35, df = 1). This equated
to an average reduction in vascular calcium concen-
tration of ~40 % (male preterm, 26.6 ± 2.4 vs. female
preterm, 23.7 ± 0.9 μg/mg, male term, 22.5 ± 2.1 μg/mg
and female term, 23 ± 2.2 μg/mg) following MgSO4 treat-
ment. An overall effect of sex could also be observed
(main effect of sex, P = 0.05, F = 18.15, df = 2) in vascular
calcium concentrations. In male preterm placental vas-
cular tissue, calcium concentrations were significantly
higher when compared to female preterm vascular tissue
following MgSO4 (male, 9.2 ± 1.5 μg/mg vs. female,
5.2 ± 0.7 μg/mg, male term, 6.1 ± 2.0 μg/mg, female
term, 5.1 ± 1.4 μg/mg). No further effects of term or in-
teractions were observed. Following post hoc analysis,
intravascular calcium prior to MgSO4 treatment was sig-
nificantly (P < 0.05) increased in male preterm vessels
when compared to all other groups. Following MgSO4
treatment, male preterm vascular calcium concentrations
were further significantly increased (P < 0.01) when com-
pared to all other groups (Fig. 6).
Discussion
This is the first report of the sex-specific and dose-
dependent effect of MgSO4 on acute regulation of vascu-
lar reactivity in human placental chorionic plate vessels.
Using small vessel pressure myography, we have demon-
strated significant effects of sex on placental vasodilata-
tion in response to MgSO4 treatment, specifically the
vasculature of male preterm placentae having reduced
vasodilatory responses to MgSO4 when compared with
female placental vessels. Additionally, we provide evi-
dence that these differences are likely, in part, due to
competitive binding and inhibition of calcium channels
and perturbation of EDHF pathways. Simultaneous ana-
lysis of vasomotor reactivity and [Ca2+]i show that the
specific mechanism of MgSO4-induced vasodilation is
primarily caused by a decrease in vascular smooth
muscle [Ca2+]i.
Consistent with published data, we observed a signifi-
cant effect of MgSO4 on the modulation of vascular
pathways related to smooth muscle function, specifically
calcium homeostasis and EDHF function. This was
manifest as a significant reduction in MgSO4-induced
vasodilation in all vessels following inhibition of both
NO and prostaglandin vasodilatory pathways. Although
specific binding sites are not affected by MgSO4, com-
petitive binding of non-specific calcium-binding sites
are. Therefore, MgSO4 is likely to alter the efficacy of
calcium to maintain a ‘normal’ maximum tension or
vasodilation when applied to vascular smooth muscle by
reducing the translocation of calcium into smooth
muscle. Corroboratory evidence for this comes from our
demonstration of a consistently higher vascular [Ca2+]i
in male preterm vessels when compared to female pre-
term placental chorionic plate vessels following incuba-
tion with MgSO4. This suggests that MgSO4 has a role
in preventing free calcium uptake into the smooth
muscle of these vessels, thus reducing basal vascular
tone and promoting vasodilation. Moreover, it has been
shown that Ca2+ blocks glutamate-activated Ca2+ and
may stabilise fluctuations in blood pressure and heart
rate and increase cerebral blood flow. Abad et al.
previously reported MgSO4 treatment in preeclamptic
pregnant women modified both Ca-ATPase activity and
Fig. 4 Relaxation induced by bradykinin following pre-constriction
with U46619 following incubation with MgSO4 (0.2 mmol/l), L-NAME
(0.1 mmol/l) and INDO ( μmol/l) in vessels isolated from male term
pregnancies (empty circle) n = 10, female term pregnancies (empty
triangle) n = 10, male preterm pregnancies (filled circle) n = 7 and
female preterm pregnancies (filled triangle) n= 7. Data was analysed
using a repeated measures three-way ANOVA using treatment × term ×
sex as the main factors. All observations were made in a minimum of
two vessels per placenta, and the average responses were calculated
before further statistical analysis. n refers to the number of placenta
used. *Denotes P < 0.01 in all cases significant difference between male
preterm and all other groups following post hoc analysis. All data are
presented as means ± SEM
Gray et al. Biology of Sex Differences  (2015) 6:22 Page 6 of 9
reduced lipid peroxidation concentrations in red blood
cell membranes. They concluded that the inhibitory ac-
tion of MgSO4 on lipid peroxidation accounts for an in-
crease in Ca-ATPase activity to normotensive pregnancy
concentrations. They hypothesised that this increases
vasodilatation and potentially decreases maternal periph-
eral vascular resistance which may explain reduction in
preeclamptic seizures [28]. The significant decrease in
vasoconstriction and [Ca2+] in female vessels and de-
creased effects of MgSO4 observed on male placental ves-
sels shows that a decreased capacity to regulate [Ca2+]i
homeostasis and impairment of Ca2+ transport are likely
to play a role in the sex-specific differences of
MgSO4-induced relaxation of placental vessels. This may
be a key determinant in restoring optimal perfusion and
nutrient supply to a foetus at risk of imminent preterm
birth, whether consequent on preterm labour reducing
placental perfusion or as a consequence of whichever
pathological process initiated the need for ‘elective’ pre-
term delivery.
The current study has shown that vasodilatory re-
sponses to bradykinin in small placental chorionic plate
vessels isolated from term and preterm were similar
across group and sex when vascular inhibition of NO
generation and PGI2 alone was performed. These results
may indicate that in the absence of NO, PGI2 pathways
may mediate vasodilatation. In the endothelium, MgSO4
has been shown to increase prostaglandin I2 production
and increases NO production causing vasodilation [29].
Although we report no difference in response to brady-
kinin in untreated vessels, analysis revealed differences
in endothelium-dependent vasoresponsiveness to brady-
kinin in vessels from term vs. preterm groups following
incubation with L-NAME, indomethacin, TRAM-34,
apamin and MgSO4. The response to bradykinin in iso-
lated vessels from term and preterm placentas shared
some similarities, in that responses were unaffected by
partial depolarisation. However, relaxation was signifi-
cantly reduced by blockade of the NO and PGI2 path-
ways in male and female preterm placental vessels. This
may indicate a reduced depolarization potential to EDHF
in male preterm placental vessels.
Recommended clinical obstetric practice in the Capital
and Coast District Health Board, Wellington, is to re-
strict the use of MgSO4 when delivery is anticipated at,
or below, 30 weeks of gestation although use in other
centres is more liberal [9, 30]. For this reason, we were
able to study a population of women who delivered pre-
maturely, yet did not receive MgSO4 as part of their rou-
tine care. Whether the sex-specific effects of MgSO4
would be greater at a lesser gestation is therefore
unknown and may be difficult to answer given the
widespread use of MgSO4 in this clinical population.
Although, the mechanisms underlying the sex-specific
vascular function in preterm placentae could not be fully
elucidated in the current study. We have demonstrated
Fig. 5 a Relaxation induced by bradykinin following pre-constriction with U46619 following incubation with MgSO4 (0.2 mmol/l), INDO (10 μmol/l),
TRAM-34 (1 μM) and apamin (3 μM) in vessels isolated from male term pregnancies (empty circle) n = 10, female term pregnancies (empty triangle)
n = 10, male preterm pregnancies (filled circle) n = 7 and female preterm pregnancies (filled triangle) n = 7. Data was analysed using a repeated measures
three-way ANOVA using treatment × term× sex as the main factors. All observations were made in a minimum of two vessels per placenta, and the
average responses were calculated before further statistical analysis. n refers to the number of placenta used. All data are presented as means ± SEM.
b Relaxation induced by bradykinin following pre-constriction with U46619 following incubation with MgSO4 (0.2 mmol/l) and indomethacin
(10 μmol/l) in vessels isolated from male term pregnancies (empty circle) n = 10, female term pregnancies (empty triangle) n = 10, male preterm
pregnancies (filled circle) n = 7 and female preterm pregnancies (filled triangle) n = 7. Data was analysed using a repeated measures three-way ANOVA
using treatment x term x sex as main factors. All observations were made in a minimum of two vessels per placenta and the average responses
calculated before further statistical analysis. n refers to the number of placenta used. All data are means ± SEM. c Relaxation induced by bradykinin
following pre-constriction with U46619 following incubation with MgSO4 (0.2 mmol/l), TRAM-34 (1 μM) and Apamin (3 μM) in vessels isolated from
male term pregnancies (empty circle) n = 10, female term pregnancies (empty triangle) n = 10, male preterm pregnancies (filled circle) n = 7 and
female preterm pregnancies (filled triangle) n = 7. Data was analysed using a repeated measures three-way ANOVA using treatment × term ×
sex as the main factors. All observations were made in a minimum of two vessels per placenta and the average responses calculated before
further statistical analysis. n refers to the number of placenta used. All data are presented as means ± SEM
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that MgSO4 treatment at currently recommended thera-
peutic concentrations improves vascular responsiveness in
placental vessels in both term and preterm placentae in a
dose-dependent manner. Furthermore, this study provides
direct evidence that the mechanism of MgSO4-induced
relaxation in placental vessels involves a reduction in vas-
cular [Ca2+]i and more importantly is significantly attenu-
ated in the placentae of preterm males compared to
preterm females. We therefore promote the concept that
it is no longer acceptable to pool placental data or make
assumptions of placental function without acknowledging
the specific sex of the placenta. Accordingly, future studies
of placental function or perinatal intervention must be ad-
equately powered to account for placental sex as an inde-
pendent factor when considering experimental design and
statistical analysis.
MgSO4 has been previously shown to increase vascular
relaxation in the aorta, resistance vessels and placental
perfusion in animal models and humans [31]. Similarly,
our results suggest that perfusion of the preterm placenta
is improved by maternal MgSO4 treatment and is likely
due to increased plasma Mg resulting in competitive in-
hibition of calcium channels. This suggests that the effect
of increased Mg+ competitively inhibiting Ca2+ entry into
the smooth muscle is the primary causal factor in mediat-
ing vasodilation. Our findings support the hypothesis that
the more specific action of MgSO4 on placental vascular
function may primarily be governed by alterations in cal-
cium homeostasis [32, 33]. Furthermore, the significant
reductions in male preterm placental vasodilatory capacity
is caused by EDHF-induced vasodilation and altered vas-
cular [Ca2+]i homeostasis and is likely to be the major
mechanism involved in these sex-specific differences of
MgSO4-induced relaxation in preterm placentae.
Conclusions
In summary, we have examined the effects of MgSO4 on
vascular tone in male and female placental vessels from
term and preterm deliveries. Our results demonstrate
that male and female foetuses may employ sex-specific
survival strategies when presented with adverse maternal
environments and associated pregnancy complications.
Data presented here provide evidence that the placenta
functions in a sex-specific manner and the overall neuro-
protective effects of MgSO4 are most marked in preterm
females as their placental bed is able to maximally relax in
response to MgSO4, thus improving foetal nutrient de-
livery and gas exchange in the peri-partum period. This
could be a major contributing factor in explaining that the
sex-specific differences in perinatal morbidity and mortal-
ity may be due to sexually dimorphic placental adaptations
during pregnancy and the relatively high neonatal mor-
bidity and ongoing male disadvantage seen in Neonatal
Units. However, clinical trials of MgSO4 have not yet ad-
dressed sex-specific long-term outcomes. In this era of
pharmacogenetic where individualised drug therapy is the
focus of much research interest, future advances in peri-
natal care need to be powered appropriately to incor-
porate the effect of foetal and therefore placental sex on
outcomes of interest.
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